

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/283650 A1

- (51) **International Patent Classification:**
G01N 33/68 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/US2022/073576
- (22) **International Filing Date:**
08 July 2022 (08.07.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 63/220,434 | 09 July 2021 (09.07.2021) | US |
| 63/203,444 | 22 July 2021 (22.07.2021) | US |
| 63/263,255 | 29 October 2021 (29.10.2021) | US |
| 63/263,928 | 11 November 2021 (11.11.2021) | US |
| 63/264,551 | 24 November 2021 (24.11.2021) | US |
| 63/306,028 | 02 February 2022 (02.02.2022) | US |
| 63/269,372 | 15 March 2022 (15.03.2022) | US |
| 63/364,618 | 12 May 2022 (12.05.2022) | US |

(71) **Applicant: EISAI R&D MANAGEMENT CO., LTD.**
[—/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo,
Ibaraki 112-8088 (JP).

(72) **Inventor; and**

(71) **Applicant: SWANSON, Chad** [US/US]; c/o Eisai Inc.,
100 Tice Blvd., Woodcliff Lake, New Jersey 07677 (US).

(72) **Inventors: KOYAMA, Akihiko**; c/o Eisai Inc., 100
Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **KANEKIYO, Michio**; c/o Eisai Inc., 100 Tice Blvd.,
Woodcliff Lake, New Jersey 07677 (US). **IRIZARRY, Michael**; c/o Eisai Inc., 100 Tice Blvd., Woodcliff Lake,
New Jersey 07677 (US). **KRAMER, Lynn**; c/o Eisai Inc.,
100 Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **KAPLOW, June**; c/o Eisai Inc., 100 Tice Blvd., Wood-
cliff Lake, New Jersey 07677 (US). **VERBEL, David**; c/
o Eisai Inc., 100 Tice Blvd., Woodcliff Lake, New Jer-
sey 07677 (US). **DHADDA, Shobha**; c/o Eisai Inc., 100
Tice Blvd., Woodcliff Lake, New Jersey 07677 (US). **SACHDEV, Pallavi**; c/o Eisai Inc., 100 Tice Blvd., Wood-
cliff Lake, New Jersey 07677 (US). **REYDERMAN, Lar-
isa**; c/o Eisai Inc., 100 Tice Blvd., Woodcliff Lake, New
Jersey 07677 (US). **HAYATO, Seiichi**; c/o Eisai Co. Ltd.,
6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, Ibaraki
112-8088 (JP). **LANDRY, Ishani**; c/o Eisai Inc., 100 Tice
Blvd., Woodcliff Lake, New Jersey 07677 (US). **GOR-
DON, Robert**; c/o Eisai Europe Ltd, EMEA Knowledge
Centre, Mosquito Way, Hatfield Hertfordshire AL10 9SN
(GB).

(74) **Agent: JACOBSTEIN, Jeffrey M.**; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 901 New York Avenue,
NW, Washington, District of Columbia 20001-4413 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) **Title:** BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT

(57) **Abstract:** Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.



WO 2023/283650 A1